SOURCE: Medistem Laboratories

January 30, 2007 09:05 ET

Medistem Scientists Co-Author Paper Proposing New Leukemia Treatment

Novel Use of Existing Drug Outlined in Journal of Translational Medicine

SCOTTSDALE, AZ -- (MARKET WIRE) -- January 30, 2007 -- Medistem Laboratories, Inc. (OTCBB: MDSM) (FRANKFURT: S2U) announced the publication of a peer reviewed paper proposing a novel approach for treatment of chronic myeloid leukemia using a clinically approved drug already on the market for unrelated symptoms. Chronic myeloid leukemia is a disease of the blood forming bone marrow stem cell. The disease affects 1 to 2 people per 100,000 and accounts for 7 - 20% cases of leukemia.

The paper was co-authored by Annette Marleau from Scripps Research Institute's Department of Immunology, Dr. Jeffrey Lipton from the University of Toronto, as well as Medistem's CEO Neil Riordan and its Chief of Scientific Development Thomas Ichim. Through collaborating with these opinion leaders, Medistem scientists have developed the unique hypothesis that a clinically used topical immunomodulator may be useful for the treatment of this particular type of leukemia. This hypothesis, which builds upon the findings of numerous other scientists, essentially proposes that the immune system is capable of controlling leukemia under defined conditions. The proposal being that these conditions may be partially attained through the use of an existing drug.

The paper titled "Therapeutic use of Aldara in chronic myeloid leukemia" was published in the January 25th, 2007 issue of the Journal of Translational Medicine and can be found at http://www.translational-medicine.com/content/pdf/1479-5876-5-4.pdf

"Medistem scientists and collaborators are highly interested not only in the natural function and utilization of healthy stem cells, but also in the biological changes that occur when stem cells become cancerous," said Neil Riordan, CEO of Medistem. "This paper is an example of ideas generated when companies collaborate with Institutions and other bodies interested in developing novel uses for existing products."

In summing up the paper, Medistem's Chief of Scientific Development Thomas Ichim noted, "Through publishing and disseminating this potential approach for the treatment of leukemia, Medistem hopes to spur scientific interest in the relationship between stem cells and the immune system, an area in which Medistem has an extensive IP portfolio."

About Medistem Laboratories, Inc.

Medistem Laboratories is an innovative biotechnology company committed to the creation and commercialization of advanced medical therapies based on non-controversial adult stem cells. Medistem's corporate mission is to transform these stem cells into valuable medical treatments. The Company's business strategy calls for the establishment of a series of clinics and laboratories around the world to deliver unprecedented, next-generation cell therapies to help millions of patients while seeking to commercialize products in the U.S. market. Clinic treatments use proprietary technology and cells sourced from umbilical cords, fat, bone marrow, and muscle for the treatment of cerebral palsy, stroke, cardiovascular disease and orthopedic diseases. Medistem believes it may hold a substantial competitive edge in the worldwide emerging market for stem cell-sourced medical solutions, positioning it to become a leading global provider of stem cell treatments on a fee-for-service basis, while accumulating intellectual property based on clinical and laboratory findings.

Cautionary Statement

This document does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This document contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may include projections of matters that affect revenue, the ability to develop or license certain technologies; operating expenses or net earnings; projections of capital expenditures; projections of growth; hiring plans; plans for future operations; financing needs or plans; plans relating to the company's products and services; and assumptions relating to the foregoing.

Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information.

Some of the important factors that could cause the company's actual results to differ materially from those projected in forward-looking statements made by the company include, but are not limited to, the following: technology development limitations, intense competition, risk of business interruption, management of rapid growth, need for additional financing, regulatory approvals and requirements, dependence on key personnel and research, management and other administrative costs.

These factors are discussed in greater detail in the company's quarterly and annual periodic reports, all as filed with the Securities and Exchange Commission.

Contact Information

  • Contact:
    Medistem Laboratories, Inc.
    Chris McGuinn
    602-318-3535